Skye Bioscience (SKYE) Revenue (2013 - 2014)
Skye Bioscience's (SKYE) quarterly Revenue came in at $136175.0 in Q2 2014, up 25.01% year-over-year from $108929.0 in Q2 2013, and up 64.37% quarter-over-quarter from $82845.0 in Q4 2013.
Powered by 
Analysis
Skye Bioscience (SKYE) Revenue (2013 - 2014) Analysis & Trends
Skye Bioscience (SKYE) has reported Revenue for 2 consecutive years, with $136175.0 the latest figure, recorded in Q2 2014.
- On a quarterly basis, Revenue rose 25.01% year-over-year to $136175.0 in Q2 2014; TTM through Apr 2014 was $419101.0, a N/A change from a year earlier, with the FY2013 full-year figure at $339926.0, up 1992.75% from the prior year.
- Revenue was $136175.0 for Q2 2014 at Skye Bioscience, up from $82845.0 in the prior quarter.
- Over five years, Revenue peaked at $136175.0 in Q2 2014 and troughed at $57130.0 in Q1 2013.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 10.05 Bn |
| 2 | Gilead Sciences | 180.02 Bn | 176.84 Bn | 6.22 Bn | 7.80 Bn |
| 3 | Vertex Pharmaceuticals | 131.54 Bn | 123.69 Bn | 2.84 Bn | 3.33 Bn |
| 4 | Regeneron Pharmaceuticals | 81.96 Bn | 73.96 Bn | 3.93 Bn | 4.29 Bn |
| 5 | Argenx Se | 60.23 Bn | 55.04 Bn | 1.37 Bn | 1.52 Bn |
| 6 | Moderna | 53.85 Bn | 48.72 Bn | 52.00 Mn | 145.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.13 Bn | 29.82 Bn | 992.69 Mn | 1.29 Bn |
| 8 | Biogen | 31.88 Bn | 30.59 Bn | 1.96 Bn | 2.74 Bn |
| 9 | Roivant Sciences | 29.23 Bn | 29.23 Bn | 1.16 Mn | 1.44 Mn |
| 10 | Skye Bioscience | 10.44 Mn | 10.44 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2014 | 136,175.00 |
| Oct 31, 2013 | 82,845.00 |
| Jul 31, 2013 | 91,152.00 |
| Apr 30, 2013 | 108,929.00 |
| Jan 31, 2013 | 57,130.00 |